Most recently, a phase I trial of a MVA vaccine expressing wild-type p53 (MVAp53) administered in combination with gemcitabine chemotherapy in platinum-resistant ovarian cancers showed that ~50% of patients had increased levels of p53-reactive CD4+ and CD8+ T-cells which significantly correlated with a longer progression-free survival (PFS) of 7.0 months in comparison to vaccinated patients with no-detected cellular response (2.3 months) [26]. This evidence concerns the gene TP53 and ovarian cancer.